IVI Foundation, Insituto de Investigación Sanitaria La Fe, Valencia, Spain.
IVI RMA, Madrid, Spain.
Front Endocrinol (Lausanne). 2021 Feb 24;11:626322. doi: 10.3389/fendo.2020.626322. eCollection 2020.
Premature ovarian insufficiency is a common disorder affecting young women and represents the worst-case ovarian scenario due to the substantial impact on the reproductive lifespan of these patients. Due to the complexity of this condition, which is not fully understood, non-effective treatments have yet been established for these patients. Different experimental approaches are being explored and strategies based on stem cells deserve special attention. The regenerative and immunomodulatory properties of stem cells have been successfully tested in different tissues, including ovary. Numerous works point out to the efficacy of stem cells in POI treatment, and a wide range of clinical trials have been developed in order to prove safety and effectiveness of stem cells therapy-in diminished ovarian reserve and POI women. The main purpose of this review is to describe the state of the art of the treatment of POI involving stem cells, especially those that use mobilization of stem cells or paracrine signaling.
卵巢早衰是一种常见的疾病,影响年轻女性,由于对这些患者的生殖寿命有重大影响,因此代表了最糟糕的卵巢情况。由于这种情况的复杂性尚未完全了解,因此尚未为这些患者建立非有效的治疗方法。正在探索不同的实验方法,基于干细胞的策略值得特别关注。干细胞的再生和免疫调节特性已在包括卵巢在内的不同组织中得到成功测试。许多研究指出干细胞在 POI 治疗中的功效,并且已经开发了广泛的临床试验,以证明干细胞疗法在卵巢储备减少和 POI 女性中的安全性和有效性。本综述的主要目的是描述涉及干细胞的 POI 治疗的最新技术,特别是那些使用干细胞动员或旁分泌信号的治疗方法。